News Atara Biotherapeutics, Inc.

Equities

ATRA

US0465131078

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
0.7149 ^USD	+4.89%		-0.39%	+39.41%

Apr. 01	Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating	MT
Mar. 29	Eric Dobmeier Not to Stand for Re-Election as Member of Board of Directors of Atara Biotherapeutics, Inc	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Apr. 05	BU
Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating	Apr. 01	MT
Eric Dobmeier Not to Stand for Re-Election as Member of Board of Directors of Atara Biotherapeutics, Inc	Mar. 29	CI
Atara Biotherapeutics: Q4 Earnings Snapshot	Mar. 28	AQ
Atara Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress	Mar. 28	BU
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q4 Revenue $4.3M	Mar. 28	MT
Atara Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 28	CI
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
North American Morning Briefing : Markets on Hold -2-	Mar. 20	DJ
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
Atara Says ATA3219 IND Application Approved by FDA for Lupus Nephritis CAR T-Cell Therapy	Feb. 29	MT
Atara Biotherapeutics Gets FDA Clearance for ATA3219 IND Application	Feb. 29	DJ
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy	Feb. 29	BU
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference	Feb. 28	BU
Atara Biotherapeutics Submits New Drug Application to FDA for ATA3219 to Treat Lupus Nephritis	Feb. 14	MT
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis	Feb. 14	BU
Atara Biotherapeutics, Inc. Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis	Feb. 14	CI
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology	Jan. 31	BU
Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology	Jan. 31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Atara Biotherapeutics, Inc.

Equities

ATRA

US0465131078

Summary

Filters